enGene Holdings Inc.ENGNNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank80
3Y CAGR+37.5%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+37.5%/yr
Quarterly compound
Percentile
P80
Within normal range
vs 3Y Ago
2.6x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 40.52% |
| Q3 2025 | 11.71% |
| Q2 2025 | 1.18% |
| Q1 2025 | 77.18% |
| Q4 2024 | -2.39% |
| Q3 2024 | 17.19% |
| Q2 2024 | 74.80% |
| Q1 2024 | -0.58% |
| Q4 2023 | 45.37% |
| Q3 2023 | 21.34% |
| Q2 2023 | -12.42% |
| Q1 2023 | -27.72% |
| Q4 2022 | 15.59% |
| Q3 2022 | 28.22% |
| Q2 2022 | 0.00% |
| Q4 2021 | 0.00% |